{
  "id": 6638,
  "url": "https://nnemf.org/research/6638-synthesis-biological-evaluation-molecular-docking-molecular-dynamics-simulation",
  "title": "Synthesis, biological evaluation, molecular docking, molecular dynamics simulation, and ADME studies of novel carbazole-aniline hybrids as cytotoxic agents.",
  "authors": [
    "Mahkameh Moradimehrabadi",
    "Soghra Khabnadideh",
    "Leila Emami",
    "Hanieh Mostashfi",
    "Negin Khajehpour",
    "Mobina Firozbakhsh",
    "Sara Sadeghian",
    "Zahra Rezaei"
  ],
  "journal": "BMC chemistry",
  "year": "2026",
  "doi": "10.1186/s13065-026-01744-x",
  "pmid": "41691293",
  "abstract": "A novel series of seven carbazole-aniline hybrids (5a-5 g) were designed, synthesized, and evaluated as potential anticancer agents. Among them, compound 5e, bearing a para-methoxy substituent, emerged as the most potent candidate, demonstrating significant cytotoxicity against breast cancer (MCF-7) and colon cancer (SW480) cell lines with IC₅₀ values of 26.4 ± 2.54 µM and 34.5 ± 1.69 µM, respectively. Notably, its activity against MCF-7 was comparable to the reference drug Erlotinib (IC₅₀ = 39.3 µM). Structure-activity relationship studies revealed that electron-donating groups significantly enhance cytotoxic effects, while electron-withdrawing substitutions diminish activity. Molecular docking studies showed that compound 5e binds effectively to the EGFR active site with a binding energy of -8.6 kcal/mol, forming key hydrogen bonds with critical residues Asp831 and Thr766. Molecular dynamics simulations further confirmed the stability of the 5e-EGFR complex. In silico ADME predictions indicated favorable drug-like properties for all compounds, consistent with Lipinski's Rule of Five. Based on its potent cytotoxicity, strong target binding, and optimal pharmacokinetic profile, compound 5e is identified as a promising lead candidate for further development as an EGFR-targeting anticancer agent.",
  "effect": "benefit",
  "evidence": "low",
  "extraction": {
    "studyType": "in_vitro",
    "studyTypeLabel": "In vitro study",
    "effectDirection": "benefit",
    "evidenceLabel": "Low",
    "population": "—",
    "sampleSize": "—",
    "exposure": "RF 100–3000 MHz",
    "confidencePct": "74",
    "peerReviewed": "yes",
    "mainFindings": "Seven carbazole-aniline hybrids (5a–5g) were synthesized and evaluated for cytotoxicity; compound 5e showed the strongest activity with IC50 26.4 ± 2.54 µM (MCF-7) and 34.5 ± 1.69 µM (SW480), with MCF-7 activity comparable to erlotinib (IC50 39.3 µM). Docking indicated 5e binds the EGFR active site (binding energy −8.6 kcal/mol) with hydrogen bonds to Asp831 and Thr766, and molecular dynamics suggested a stable 5e–EGFR complex; ADME predictions were favorable for all compounds and consistent with Lipinski’s Rule of Five.",
    "outcomes": [
      "Cytotoxicity (IC50) in MCF-7 breast cancer cell line",
      "Cytotoxicity (IC50) in SW480 colon cancer cell line",
      "EGFR binding energy (molecular docking)",
      "Stability of 5e–EGFR complex (molecular dynamics simulation)",
      "In silico ADME / drug-likeness (Lipinski Rule of Five)"
    ],
    "limitations": [],
    "keywords": [
      "carbazole-aniline hybrids",
      "cytotoxicity",
      "MCF-7",
      "SW480",
      "EGFR",
      "molecular docking",
      "molecular dynamics",
      "ADME",
      "Lipinski"
    ],
    "hubs": [],
    "raw": "{\n  \"study_type\": \"in_vitro\",\n  \"exposure\": {\n    \"band\": null,\n    \"source\": null,\n    \"frequency_mhz\": null,\n    \"sar_wkg\": null,\n    \"duration\": null\n  },\n  \"population\": null,\n  \"sample_size\": null,\n  \"outcomes\": [\n    \"Cytotoxicity (IC50) in MCF-7 breast cancer cell line\",\n    \"Cytotoxicity (IC50) in SW480 colon cancer cell line\",\n    \"EGFR binding energy (molecular docking)\",\n    \"Stability of 5e–EGFR complex (molecular dynamics simulation)\",\n    \"In silico ADME / drug-likeness (Lipinski Rule of Five)\"\n  ],\n  \"main_findings\": \"Seven carbazole-aniline hybrids (5a–5g) were synthesized and evaluated for cytotoxicity; compound 5e showed the strongest activity with IC50 26.4 ± 2.54 µM (MCF-7) and 34.5 ± 1.69 µM (SW480), with MCF-7 activity comparable to erlotinib (IC50 39.3 µM). Docking indicated 5e binds the EGFR active site (binding energy −8.6 kcal/mol) with hydrogen bonds to Asp831 and Thr766, and molecular dynamics suggested a stable 5e–EGFR complex; ADME predictions were favorable for all compounds and consistent with Lipinski’s Rule of Five.\",\n  \"effect_direction\": \"benefit\",\n  \"limitations\": [],\n  \"evidence_strength\": \"low\",\n  \"confidence\": 0.74,\n  \"peer_reviewed_likely\": \"yes\",\n  \"keywords\": [\n    \"carbazole-aniline hybrids\",\n    \"cytotoxicity\",\n    \"MCF-7\",\n    \"SW480\",\n    \"EGFR\",\n    \"molecular docking\",\n    \"molecular dynamics\",\n    \"ADME\",\n    \"Lipinski\"\n  ],\n  \"suggested_hubs\": []\n}"
  },
  "synthesis": null,
  "synthesisStatus": "pending",
  "originalHref": "https://pubmed.ncbi.nlm.nih.gov/41691293/",
  "sourceUrl": "https://rfsafe.org/mel/paper.php?id=6638",
  "updated": "2026-02-17 03:52:59"
}